<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029402</url>
  </required_header>
  <id_info>
    <org_study_id>16-118</org_study_id>
    <nct_id>NCT04029402</nct_id>
  </id_info>
  <brief_title>Molecular Analysis of Diabetic Kidney Disease Biopsies</brief_title>
  <official_title>Molecular Analysis of Diabetic Kidney Disease Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite decades of research, the pathogenesis of human diabetic kidney disease remains&#xD;
      largely unclear. Our goal is to use archived human kidney biopsy tissue from patients with&#xD;
      and with diabetic nephropathy to identify new molecules that drive and/or protect against&#xD;
      disease progression. We will use RNA sequencing to identify transcriptomic changes that&#xD;
      associate with histologic and functional outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH OBJECTIVES A. To identify differences in transcription profiles obtained from&#xD;
      residual kidney tissue which was obtained for clinical purposes.&#xD;
&#xD;
      B. To identify differences in transcription profile between patients whose loss of kidney&#xD;
      function progresses rapidly (eGFR decline ≥4ml/min/year) and in whom it progresses more&#xD;
      slowly (eGFR decline &lt;4ml/min/year).&#xD;
&#xD;
      C. To identify differences in transcription profile between predominantly glomerular and&#xD;
      predominantly tubulointerstitial histopathological types .&#xD;
&#xD;
      D. To identify new pathogenetic pathways that may become targets for therapeutic intervention&#xD;
&#xD;
      METHODS The planned study centres on the use of archival biopsy material that is superfluous&#xD;
      to what is or would be needed for clinical care (01/01/1995 to 31/05/2018 , n= approximately&#xD;
      400-500). Archived samples will be collected from St. Michael's Hospital and a number of&#xD;
      collaborating centres, including but not limited to University of British Columbia, the&#xD;
      University of Manitoba, and the University of Ottawa.&#xD;
&#xD;
      RNA will be extracted from the biopsy material using either the core that has been used for&#xD;
      immunofluorescence microscopy and is stored at -80˚C, and/or the core that is formalin-fixed,&#xD;
      embedded in paraffin wax and stored at room temperature. The RNA thereby extracted will be&#xD;
      subjected to detailed interrogation by RNASeq to quantify the expression level of mRNAs&#xD;
      (transcriptome) and compare differences, as indicated in the research objectives detailed&#xD;
      above. The transcriptome will then be related to the clinical course (eGFR decline) and&#xD;
      histopathological changes, in addition to examining potentially pathogenetically important&#xD;
      and that are amenable to therapeutic intervention.&#xD;
&#xD;
      Histopathology will also be performed and classified according to established systems.&#xD;
&#xD;
      Clinical information that would be retrieved from patients' medical records are listed below.&#xD;
&#xD;
      Clinical data&#xD;
&#xD;
        1. Age&#xD;
&#xD;
        2. Gender&#xD;
&#xD;
        3. Ethnicity&#xD;
&#xD;
        4. Diabetes history&#xD;
&#xD;
        5. Diabetes type: 1, 2&#xD;
&#xD;
        6. Retinopathy history&#xD;
&#xD;
        7. Smoking history&#xD;
&#xD;
        8. Medications&#xD;
&#xD;
        9. Comorbidities&#xD;
&#xD;
       10. Past medical history&#xD;
&#xD;
       11. Primary nephrologist Laboratory data (prior to biopsy, at biopsy and post-biopsy)&#xD;
&#xD;
       12. Renal function measures and calculations. For example:&#xD;
&#xD;
           i. Serum creatinine, eGFR ii. Change in creatinine and eGFR iii. Urinary&#xD;
           albumin:creatinine values and ratio (ACR) iv. Urine protein:creatinine values and ratio&#xD;
           (PCR) v. Urinary protein excretion rate (UPEx) vi. Changes in ACR, PCR, UPEx&#xD;
&#xD;
       13. Diabetes measures and calculations. Biopsy data&#xD;
&#xD;
       14. Biopsy related data&#xD;
&#xD;
      Each site will locally maintain a confidential Master Linking Log.&#xD;
&#xD;
      De-identified data will be entered into a secure REDCap database that is hosted by St.&#xD;
      Michael's Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial fibrosis</measure>
    <time_frame>Baseline biopsy</time_frame>
    <description>Extent of interstitial fibrosis in kidney biopsy assessed using a semi-quantitative scale on light microscopy of biopsy sections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerulosclerosis</measure>
    <time_frame>Baseline biopsy</time_frame>
    <description>Extent of glomerulosclerosis in kidney biopsy assessed using a semi-quantitative scale on light microscopy of biopsy sections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function change</measure>
    <time_frame>Baseline biopsy</time_frame>
    <description>Slope of eGFR decline</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <condition>Kidney Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Diabetic kidney disease</arm_group_label>
    <description>Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RNA sequencing</intervention_name>
    <description>Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline</description>
    <arm_group_label>Diabetic kidney disease</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Histology</other_name>
    <other_name>Slope of eGFR decline</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Cases: A group of patients with diabetic kidney disease&#xD;
&#xD;
          2. Controls: A group of healthy control patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (diabetic kidney disease cases):&#xD;
&#xD;
          -  history of type 1 or type 2 diabetes&#xD;
&#xD;
          -  at least 1 archived native kidney biopsy that demonstrates either pure diabetic kidney&#xD;
             disease or features of non-specific vascular disease, including glomerulosclerosis,&#xD;
             non-inflammatory vascular disease,&#xD;
&#xD;
          -  sufficient remaining archived kidney biopsy tissue for RNA sequencing (100 um thick&#xD;
             tissue section) and histologic analysis (PAS and Masson Trichrome staining)&#xD;
&#xD;
        Exclusion Criteria (diabetic kidney disease cases):&#xD;
&#xD;
          -  less than 3 eGFR values post-biopsy&#xD;
&#xD;
          -  latest recorded eGFR values less than 6 months post-biopsy&#xD;
&#xD;
        Inclusion Criteria (healthy controls):&#xD;
&#xD;
        - at least 1 native kidney disease biopsy with no diagnostic abnormality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Richard Gilbert, MD PhD</last_name>
    <phone>416-864-3747</phone>
    <email>richard.gilbert@utoronto.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Barbour, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Rigatto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Burns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Nash</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>3692</phone_ext>
      <email>nashm@smh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

